Thus, the combination of siRNAs targeting E6 or E6/E7 may have synergistic effects on the restoration of TP53 and/or pRB function, and may be a more effective therapeutic modality for the treatment of cervical cancer. This evidence concerns the gene RB1 and cervical cancer.